Harel Insurance Investments & Financial Services Ltd. Cellectis S.A. Transaction History

Harel Insurance Investments & Financial Services Ltd.

$5.8 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2018 Jan 29, 2019	SELL	$15.58 - $28.41 $71,403 - $130,203	-4,583 Closed	0 $0
Q3 2018 Oct 29, 2018	BUY	$25.99 - $30.6 $119,112 - $140,239	4,583 New	4,583 $129,000

Others Institutions Holding CLLS

# of Institutions

Shares Held

11.2M

Call Options Held

5.9K

Put Options Held

1.4K

Long Focus Capital Management, LLC San Juan, PR

4.62M
Shares

$8.96 Million
0.36% of portfolio
Capital International Investors Los Angeles, CA

1.85M
Shares

$3.59 Million
0.0% of portfolio
Ubs Asset Management Americas Inc Chicago, IL

1.44M
Shares

$2.79 Million
0.0% of portfolio
Credit Suisse Ag Zurich, V8

1.44M
Shares

$2.79 Million
0.0% of portfolio
Baillie Gifford & CO

694K
Shares

$1.35 Million
0.0% of portfolio

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $88.3M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Harel Insurance Investments & Financial Services Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Harel Insurance Investments & Financial Services Ltd. with notifications on news.

Account